German site
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion
For business and trade media only Positive opinion for Senaparib, as a Potential First-Line Maintenance Treatment...
More informationPharmanovia appoints Julia Schüssler as Chief People and Culture Officer and John Parsons as General Counsel to support next phase of growth
FOR IMMEDIATE RELEASE – BASILDON, UK, 17 JUNE 2026 Pharmanovia, a global specialty pharmaceutical company, has...
More informationPharmanovia announces a first-in-class drug therapy treatment
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY PHARMANOVIA ANNOUNCES LAUNCH OF KORJUNY (CATUMAXOMAB) IN...
More informationPharmanovia appoints Stephan Eder as Chief Executive Officer
For immediate release, 1st October 2025, Basildon, UK: Pharmanovia today announced the appointment of Stephan Eder as...
More informationPharmanovia Leadership Update
FOR IMMEDIATE RELEASE – BASILDON, UK, 10th APRIL 2025 Pharmanovia, a global pharmaceutical company that commercialises...
More informationPharmanovia acquires exclusive rights to novel antipsychotic treatment
BASILDON, UK, 1st April 2025 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises,...
More informationPharmanovia announces exclusive distribution agreement with Er-Kim for Sunosi® in Eastern Europe
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY Basildon, UK – 21 February 2025 Pharmanovia,...
More informationLindis Biotech and Pharmanovia announce European marketing authorisation approval for a first-in-class treatment
PRESS RELEASE – FOR TRADE AND BUSINESS MEDIA ONLY MUNICH, GERMANY, AND BASILDON, UK, 13 February...
More informationPharmanovia signs in-licensing deal for novel osteoporosis treatment with Radius Health
BASILDON, UK, 02 January 2025 Pharmanovia, a global pharmaceutical company that commercialises novel medicines and revitalises,...
More informationFor all media enquiries please contact: communications@pharmanovia.com